CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.

ABSTRACT:

Background

Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma.

Methods

A retrospective study was carried out in patients with unresectable/metastatic melanoma (stage IIIb-IV), treated with anti-PD-1 in the first line setting, to better explore the role and the timing of neutrophil/lymphocyte ratio (NLR) as potential biomarker of response. The relationship of NLR with inflammation-immune mediators and the underlying negative effect of raising NLR during immunotherapy, have been investigated with transcriptomic gene analysis.

Results

The results confirmed previous findings that a high baseline NLR is associated with a poorer prognosis and with higher serum level of lactate dehydrogenase (LDH), regardless of

SUBMITTER: Mallardo D 

PROVIDER: S-EPMC10492378 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature